JP2022518392A5 - - Google Patents
Info
- Publication number
- JP2022518392A5 JP2022518392A5 JP2021540103A JP2021540103A JP2022518392A5 JP 2022518392 A5 JP2022518392 A5 JP 2022518392A5 JP 2021540103 A JP2021540103 A JP 2021540103A JP 2021540103 A JP2021540103 A JP 2021540103A JP 2022518392 A5 JP2022518392 A5 JP 2022518392A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- vhh
- molecule
- vhh molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305031.7 | 2019-01-09 | ||
| EP19305031 | 2019-01-09 | ||
| PCT/EP2020/050318 WO2020144233A1 (en) | 2019-01-09 | 2020-01-08 | Transferrin receptor-binding molecules, conjugates thereof and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518392A JP2022518392A (ja) | 2022-03-15 |
| JP2022518392A5 true JP2022518392A5 (https=) | 2022-12-19 |
| JP7599425B2 JP7599425B2 (ja) | 2024-12-13 |
Family
ID=65236972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540103A Active JP7599425B2 (ja) | 2019-01-09 | 2020-01-08 | トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12152317B2 (https=) |
| EP (1) | EP3908608A1 (https=) |
| JP (1) | JP7599425B2 (https=) |
| CN (1) | CN113474369B (https=) |
| AU (1) | AU2020206593B2 (https=) |
| BR (1) | BR112021013559A2 (https=) |
| CA (1) | CA3124790A1 (https=) |
| EA (1) | EA202191893A1 (https=) |
| WO (1) | WO2020144233A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12258597B2 (en) | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| US20240391967A1 (en) * | 2020-12-02 | 2024-11-28 | University Health Network | Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies |
| MX2024005968A (es) * | 2021-11-19 | 2024-08-06 | Japan Chem Res | Peptido que tiene afinidad por el receptor de transferrina humano. |
| CN117377487B (zh) | 2021-12-02 | 2024-11-22 | 领诺(上海)医药科技有限公司 | 转铁蛋白结合抗体及其应用 |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| WO2023128702A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| CN119301262A (zh) | 2022-04-01 | 2025-01-10 | 武田药品工业株式会社 | 用于具有cns表现的疾病的基因疗法 |
| EP4526344A1 (en) * | 2022-05-16 | 2025-03-26 | Denali Therapeutics Inc. | Transferrin receptor-binding domains and proteins comprising the same |
| CN120659627A (zh) * | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| KR20250111123A (ko) | 2022-11-23 | 2025-07-22 | 키2브레인 에이비 | Vhh 항체 및 이의 용도 |
| US20260116990A1 (en) | 2022-11-23 | 2026-04-30 | Key2Brain Ab | Vhh antibodies and uses thereof |
| AU2023404617A1 (en) * | 2022-12-02 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-tfr1 antibodies and uses thereof |
| TW202436352A (zh) * | 2023-02-07 | 2024-09-16 | 日商Ｊｃｒ製藥股份有限公司 | 人類運鐵蛋白受體親和性肽 |
| CN116179607A (zh) * | 2023-03-27 | 2023-05-30 | 迦进生物医药(上海)有限公司 | 一种human TfR2高表达的稳转细胞株及其构建方法和应用 |
| CN116121306A (zh) * | 2023-03-27 | 2023-05-16 | 迦进生物医药(上海)有限公司 | 一种human TfR1高表达的稳转细胞株及其构建方法和应用 |
| AU2024243709A1 (en) | 2023-04-03 | 2025-11-06 | Katholieke Universiteit Leuven | Blood-brain barrier crossing antibodies |
| CN121794291A (zh) | 2023-06-22 | 2026-04-03 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途 |
| EP4731658A1 (en) | 2023-06-22 | 2026-04-29 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases |
| EP4480964A1 (en) | 2023-06-22 | 2024-12-25 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases |
| EP4480965A1 (en) | 2023-06-22 | 2024-12-25 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases |
| CN121773136A (zh) * | 2023-07-04 | 2026-03-31 | 北京星奇原生物科技有限公司 | 抗-TfR1抗体及其用途 |
| WO2025042711A1 (en) | 2023-08-18 | 2025-02-27 | Eli Lilly And Company | Engineered transferrin receptor binding peptides as well as methods of making and using the same |
| US20250064958A1 (en) * | 2023-08-22 | 2025-02-27 | Eli Lilly And Company | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS |
| WO2025194170A1 (en) * | 2024-03-15 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins |
| WO2025194171A1 (en) * | 2024-03-15 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors |
| WO2025207959A1 (en) * | 2024-03-27 | 2025-10-02 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| WO2025207946A1 (en) * | 2024-03-28 | 2025-10-02 | Genzyme Corporation | Polypeptides binding to a specific epitope of the transferrin receptor 1 |
| WO2025226642A1 (en) | 2024-04-25 | 2025-10-30 | Eli Lilly And Company | Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2441903C (en) * | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP2008666A1 (en) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
| EP2207568B1 (en) | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| FR2937322B1 (fr) | 2008-10-22 | 2013-02-22 | Vect Horus | Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues |
| FR2959229B1 (fr) | 2010-04-21 | 2013-01-18 | Vect Horus | Derives peptidiques, leur preparation et leurs utilisations |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CA2818173C (en) | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| WO2013177062A2 (en) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| CN105102478A (zh) * | 2013-01-30 | 2015-11-25 | 弗拉芒区生物技术研究所 | 用于筛选和药物发现目的的新型嵌合多肽 |
| EP2899208A1 (en) * | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| NZ724869A (en) * | 2014-03-06 | 2022-07-01 | Nat Res Council Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| EA039366B1 (ru) | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| EP3494216B1 (en) | 2016-08-06 | 2025-10-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
-
2020
- 2020-01-08 CA CA3124790A patent/CA3124790A1/en active Pending
- 2020-01-08 AU AU2020206593A patent/AU2020206593B2/en active Active
- 2020-01-08 US US17/421,412 patent/US12152317B2/en active Active
- 2020-01-08 EP EP20700450.8A patent/EP3908608A1/en active Pending
- 2020-01-08 EA EA202191893A patent/EA202191893A1/ru unknown
- 2020-01-08 JP JP2021540103A patent/JP7599425B2/ja active Active
- 2020-01-08 CN CN202080008202.4A patent/CN113474369B/zh active Active
- 2020-01-08 BR BR112021013559-6A patent/BR112021013559A2/pt unknown
- 2020-01-08 WO PCT/EP2020/050318 patent/WO2020144233A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518392A5 (https=) | ||
| JP7412521B2 (ja) | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 | |
| AU2023200616A1 (en) | Antigen binding constructs to target molecules | |
| CN104105708B (zh) | PDGF受体β结合多肽 | |
| EP2501721B1 (en) | Multivalent antibodies comprising fab-dsfv | |
| EP2523972B1 (en) | Threevalent antibodies | |
| CN106459216B (zh) | 多特异性抗体构建体 | |
| CN113045660B (zh) | 与cd8的抗原结合构建体 | |
| JP2025134874A (ja) | ブラジキニンｂ１受容体リガンドに対する抗体 | |
| US20160333105A1 (en) | Multivalent Antibodies | |
| EP2550297B1 (en) | Disulfide stabilized dvd-lg molecules | |
| JP7360720B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| KR20150093744A (ko) | Bcma 항원 결합 단백질 | |
| JP2022509372A5 (https=) | ||
| KR20240107202A (ko) | 항-트랜스페린 수용체 항체 및 이의 용도 | |
| WO2011061246A2 (en) | Multivalent antibodies | |
| JP2021512159A5 (https=) | ||
| WO2021207433A2 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| KR20210071987A (ko) | 항-cd79 항체 및 이들의 용도 | |
| JP2009529915A5 (https=) | ||
| CN114652853A (zh) | 抗il-4r抗体-药物偶联物及医药用途 | |
| WO2024022438A1 (zh) | 一种抗rbd抗体及其用途 | |
| US12161889B2 (en) | Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB | |
| WO2023071953A1 (zh) | 抗cd26抗体及其应用 | |
| WO2022156670A1 (en) | Multispecific antibodies against sars-cov-2 and methods of use thereof |